BRF2 and breast carcinoma: The IC50 of Bex correlated negatively to the expression of BRF2 among the breast cancer cell lines (the threshold of expression set to −2 to 2) (Figure 7F), unlike the other available drugs on the list (alectinib and AZD5991) (Supplementary Figure S7D,E).